CD14 and COVID-19: Indeed, large studies on the general population showed that patients in severe-stages of COVID-19 had increased amounts of circulating CD14+ CD16+ monocytes which exert inflammatory activity through increased release of IL-6 and interaction with adaptive B and T-cells [53,54].